Actuate Therapeutics, Inc. (ACTU) — SEC Filings
Actuate Therapeutics, Inc. (ACTU) — 32 SEC filings. Latest: DEFA14A (May 6, 2026). Includes 15 8-K, 5 10-Q, 5 S-1/A.
View Actuate Therapeutics, Inc. on SEC EDGAR
Overview
Actuate Therapeutics, Inc. (ACTU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 28, 2025: Actuate Therapeutics, Inc. filed an 8-K on November 28, 2025, reporting an entry into a material definitive agreement and related financial statements/exhibits. The company, formerly known as Apotheca Therapeutics, Inc. until September 11, 2015, is incorporated in Delaware and headquartered in Fort
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 2 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Actuate Therapeutics, Inc. is neutral.
Filing Type Overview
Actuate Therapeutics, Inc. (ACTU) has filed 2 DEFA14A, 15 8-K, 5 10-Q, 2 S-1, 1 DEF 14A, 1 10-K, 1 SC 13D, 5 S-1/A with the SEC between May 2024 to May 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ACTU's 29 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | $-17.7M |
| EPS | N/A |
| Debt-to-Equity | 0.63 |
| Cash Position | $16.9M |
| Operating Margin | N/A |
| Total Assets | $17.7M |
| Total Debt | $6.8M |
Key Executives
- Daniel Schmitt
- Janet Spreen, Esq.
- Aaron Glenn
- Louis Fletcher
Industry Context
Actuate Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and high failure rates for drug candidates. Success is heavily reliant on scientific innovation, clinical trial outcomes, and navigating complex regulatory pathways.
Top Tags
ipo (6) · financials (5) · material-agreement (4) · corporate-governance (4) · pharmaceuticals (4) · amendment (4) · sec-filing (4) · Biotechnology (3) · filing (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $17.7M | Reduced from $20.8M in 2024, a 15.28% improvement year-over-year. |
| Research and Development Expenses | $8.2M | Decreased by 45.54% from $15.0M in 2024. |
| General and Administrative Expenses | $9.6M | Increased by 167% from $3.6M in 2024. |
| Cash and Cash Equivalents | $16.9M | Increased from $8.6M at December 31, 2024, providing liquidity. |
| Accumulated Deficit | $150.1M | As of September 30, 2025, indicating significant historical losses. |
| Shares Outstanding | 23,243,328 | As of November 12, 2025, reflecting recent capital raises and potential dilution. |
| Additional Paid-in Capital | $15.6M | From September 2025 underwritten public offering, net of costs. |
| Proceeds from June 2025 Private Placement | $4,621,546 | net of issuance costs, contributing to financing activities |
| Proceeds from Committed Equity Facility | $2,163,100 | net of issuance costs, contributing to financing activities |
| Shares of Common Stock Outstanding | 20,745,187 | as of August 13, 2025 |
| S-1 Filing Date | 2025-07-25 | Date Actuate Therapeutics, Inc. filed its registration statement with the SEC. |
| SEC File Number | 333-288952 | Unique identifier for Actuate Therapeutics' S-1 registration statement. |
| Central Index Key (CIK) | 0001652935 | Unique identifier for Actuate Therapeutics, Inc. with the SEC. |
| Standard Industrial Classification (SIC) Code | 2834 | Indicates the company operates in 'Pharmaceutical Preparations'. |
| IRS Employer Identification Number (EIN) | 47-3044785 | Tax identification number for Actuate Therapeutics, Inc. |
Frequently Asked Questions
What are the latest SEC filings for Actuate Therapeutics, Inc. (ACTU)?
Actuate Therapeutics, Inc. has 32 recent SEC filings from May 2024 to May 2026, including 15 8-K, 5 10-Q, 5 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ACTU filings?
Across 32 filings, the sentiment breakdown is: 2 bearish, 29 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Actuate Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Actuate Therapeutics, Inc. (ACTU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Actuate Therapeutics, Inc.?
Key financial highlights from Actuate Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ACTU?
The investment thesis for ACTU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Actuate Therapeutics, Inc.?
Key executives identified across Actuate Therapeutics, Inc.'s filings include Daniel Schmitt, Janet Spreen, Esq., Aaron Glenn, Louis Fletcher.
What are the main risk factors for Actuate Therapeutics, Inc. stock?
Of ACTU's 29 assessed filings, 3 were flagged high-risk, 16 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Actuate Therapeutics, Inc.?
Forward guidance and predictions for Actuate Therapeutics, Inc. are extracted from SEC filings as they are enriched.